Chester County News and Community Website
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported breakthrough results from the Phase III DESTINY-Breast05 trial, showing that their drug ENHERTU (fam-trastuzumab deruxtecan-nxki) cut the risk of disease recurrence or …
AstraZeneca’s Enhertu Slashes Breast Cancer Recurrence Risk in Landmark Trial Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported that their antibody-drug conjugate ENHERTU® (fam-trastuzumab deruxtecan-nxki), when used before surgery and followed by standard therapy, achieved a pathologic complete response in …
ENHERTU Combination Shows Promising Results in Early Breast Cancer Trial Read More WILMINGTON, DE — AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an add-on maintenance treatment for adults and adolescents aged 12 and …
AstraZeneca and Amgen Secure FDA Approval for TEZSPIRE to Treat Chronic Rhinosinusitis with Nasal Polyps Read More WILMINGTON, DE — AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC) …
IMFINZI Combination Cuts Disease Recurrence Risk by 32% in Early Bladder Cancer Trial Read More WILMINGTON, DE — AstraZeneca announced new data from its Phase III MATTERHORN trial showing that its immunotherapy IMFINZI (durvalumab), when used in combination with standard FLOT chemotherapy, reduced the risk …
AstraZeneca Reports IMFINZI-Based Regimen Cuts Death Risk by 22% in Early Gastric Cancer Read More WILMINGTON, DE — AstraZeneca announced plans to invest $4.5 billion in a new state-of-the-art manufacturing facility in Albemarle County, Virginia, expanding its previously announced U.S. commitment by $500 million. The …
AstraZeneca Expands U.S. Investment With $4.5 Billion Manufacturing Facility in Virginia Read More
ANNAPOLIS, MD & PHILADELPHIA, PA — Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA), have announced the 2025 Care for HER program, an initiative aimed at reducing …
Unite for HER and TOUCHBBCA Expand Care for Black Breast Cancer Patients With 2025 Program Read More WILMINGTON, DE — Positive results from the Phase III Bax24 trial show that baxdrostat achieved statistically significant and clinically meaningful reductions in 24-hour systolic blood pressure (SBP) among patients with …
Baxdrostat Achieves Breakthrough Blood Pressure Reductions in Phase III Bax24 Trial Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that their jointly developed therapy, DATROWAY® (datopotamab deruxtecan-dlnk), achieved positive top-line results in the Phase III TROPION-Breast02 trial, marking a major advancement …
AstraZeneca and Daiichi Sankyo Report Breakthrough Results for DATROWAY® in Advanced Breast Cancer Trial Read More
WASHINGTON, D.C. — President Donald J. Trump on Friday announced a new agreement with pharmaceutical company AstraZeneca aimed at lowering prescription drug costs and strengthening U.S. manufacturing, part of a …
Trump Administration, AstraZeneca Reach Deal to Cut Drug Prices and Expand U.S. Investment Read More